{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00017172", "CSN": null, "TRF": "ORD_1226643_01", "MRN": "45378652", "PhysicianId": "16468", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "930484", "clinicalId": "931868", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1226643_01", "SampleName": "US1183461.01", "Version": "0", "Sample": {"FM_Id": "ORD_1226643_01", "SampleId": "US1183461.01", "BlockId": "nan", "TRFNumber": "ORD_1226643_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2021_11_01", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "20", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-89474", "MRN": "45378652", "FullName": "\u9127\u68cb\u4e9e", "FirstName": "Chi_Ya", "LastName": "Teng", "SubmittedDiagnosis": "Adenocarcinoma, Liver", "Gender": "Male", "DOB": "1963_11_23", "OrderingMD": "\u9673\u660e\u6643", "OrderingMDId": "16468", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2021_10_27", "ReceivedDate": "2021-11-15 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Adenocarcinoma, NOS"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "20", "clinicalTrialCount": "13", "resistiveCount": "0", "sensitizingCount": "4"}, "VariantProperties": {"VariantProperty": [{"geneName": "BCORL1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "C17orf39", "isVUS": "true", "variantName": "K160R"}, {"geneName": "CSF1R", "isVUS": "true", "variantName": "T621M"}, {"geneName": "FANCC", "isVUS": "true", "variantName": "A325T"}, {"geneName": "FGFR3", "isVUS": "true", "variantName": "V505I"}, {"geneName": "GABRA6", "isVUS": "true", "variantName": "R84H"}, {"geneName": "IRS2", "isVUS": "true", "variantName": "A512T"}, {"geneName": "MTOR", "isVUS": "true", "variantName": "T1834_T1837del"}, {"geneName": "PIK3C2G", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "RICTOR", "isVUS": "true", "variantName": "S443C"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "R3136C"}, {"geneName": "STAG2", "isVUS": "true", "variantName": "amplification"}, {"geneName": "ZNF703", "isVUS": "true", "variantName": "G302D"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "ARID1A", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 2732+1_2732+18del18", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 2732+1_2732+18del18"}}, "Interpretation": "ARID1A encodes the AT_rich interactive domain_containing protein 1A, also known as Baf250a, a member of the SWI/SNF chromatin remodeling complex. Mutation, loss, or inactivation of ARID1A has been reported in many cancers, and the gene is considered a tumor suppressor (Guan et al., 2011; 21900401, Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Yan et al., 2014; 24293408, Wang et al., 2012; 22808142, Huang et al., 2012; 22922871, Chan_On et al., 2013; 24185513, Mamo et al., 2012; 21892209). ARID1A mutations, which are mostly truncating, have been identified along the entire gene and often correlate with ARID1A protein loss (Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Zang et al., 2012; 22484628, Wang et al., 2011; 22037554), whereas ARID1A missense mutations are mostly uncharacterized. ARID1A alterations are particularly prevalent in ovarian clear cell carcinoma (46_50%), ovarian and uterine endometrioid carcinomas (24_44%), and cholangiocarcinoma (27%); they are also reported in up to 27% of gastric carcinoma, esophageal adenocarcinoma, Waldenstrom macroglobulinemia, pediatric Burkitt lymphoma, hepatocellular carcinoma, colorectal carcinoma, and urothelial carcinoma samples analyzed (COSMIC, cBioPortal, 2021) (Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Wu et al., 2014; 24618703, Jones et al., 2012; 22009941, Dulak et al., 2013; 23525077, Streppel et al., 2013; 23318448, Jiao et al., 2014; 24293293, Ross et al., 2014; 24563076). ARID1A loss is associated with microsatellite instability in ovarian and endometrial endometrioid adenocarcinomas (Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303, Okamura et al., 2020; 32111729), CRC (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809, Okamura et al., 2020; 32111729), and gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857, Okamura et al., 2020; 32111729). ARID1A protein loss is associated with tumors of poor histological grade for many tumor types, including colorectal cancer (CRC) (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809), cervical cancer (Katagiri et al., 2012; 22274316, Cho et al., 2013; 23427874), gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857), urothelial carcinoma (Gui et al., 2011; 21822268, Balbas_Martinez et al., 2013; 23650517, Faraj et al., 2014; 25175170), ovarian and endometrial cancers (Rahman et al., 2013; 22939958, Maeda et al., 2010; 21614196, Lowery et al., 2012; 22193641, Fadare et al., 2013; 23524907, Mao et al., 2013; 24076775, Katagiri et al., 2012; 22101352, Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303), breast carcinoma (Zhang et al., 2012; 21889920, Mamo et al., 2012; 21892209, Zhao et al., 2014; 24430365), and clear cell renal cell carcinoma (Lichner et al., 2013; 23416164); ARID1A mutation has been associated with poor outcomes for patients with cholangiocarcinoma (Feng et al., 2021; 33387086, Conci et al., 2020; 32020551, Simbolo et al., 2018; 29740198, Ruzzenente et al., 2016; 26717940). However, prognostic data regarding patient survival are often mixed and conflicting. There are no therapies approved to address the mutation or loss of ARID1A in cancer. However, on the basis of limited clinical and preclinical evidence, ARID1A inactivating mutations may lead to sensitivity to ATR inhibitors such as M6620; 1 patient with small cell lung cancer harboring an ARID1A mutation experienced a PR when treated with M6620 combined with topotecan (Thomas et al., 2018; 29252124, Williamson et al., 2016; 27958275). On the basis of limited preclinical evidence from studies in ovarian cancer, ARID1A inactivation may predict sensitivity to inhibitors of EZH2 (Bitler et al., 2015; 25686104, Kim et al., 2015; 26552009), which are under investigation in clinical trials. Other studies have reported that loss of ARID1A may activate the PI3K_AKT pathway and be linked with sensitivity to inhibitors of this pathway (Wiegand et al., 2014; 24559118, Huang et al., 2014; 24336158, Samartzis et al., 2014; 24979463). Loss of ARID1A expression has been associated with chemoresistance to platinum_based therapy in patients with ovarian clear cell carcinoma (Yokoyama et al., 2014; 24459582, Katagiri et al., 2012; 22101352) and to 5_fluorouracil (5_FU) in CRC cell lines (Xie et al., 2014; 24833095).", "Include": "true", "ClinicalTrialNote": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT02630199", "Include": "true"}, {"nctId": "NCT03641547", "Include": "true"}, {"nctId": "NCT03669601", "Include": "true"}, {"nctId": "NCT02595931", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ATM", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 6007_1G>T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 6007_1G>T"}}, "Interpretation": "ATM encodes the protein ataxia telangiectasia mutated, which is a serine/threonine protein kinase that plays a key role in the DNA damage response (Shiloh and Ziv, 2013; 23847781). Loss of functional ATM promotes tumorigenesis (Cremona and Behrens, 2014; 23851492). Alterations such as seen here may disrupt ATM function or expression (Jiang et al., 2006; 16603769, Fernandes et al., 2005; 15713674, Scott et al., 2002; 11805335). ATM mutations have been reported in 6% of samples analyzed in the COSMIC database, including carcinomas of skin (21%), endometrium (12%), urinary tract (11%), large intestine (9%), lung (6%), small intestine (6%), and biliary tract (6%)(Aug 2021)(Tate et al., 2019; 30371878). Decreased expression of ATM has been reported in patients with gastric or colorectal cancer (Wu et al., 2013; 23437304, Kang et al., 2008; 17928013, Kim et al., 2013; 23328638, Zhang et al., 2013; 23569343). High ATM protein expression has been reported to correspond with smaller tumor size, lower recurrence rate, longer patient survival, and fewer metastases in some tumors, including gastric and colorectal cancers (Shin et al., 2012; 22707287, Grabsch et al., 2006; 16533773, Lee et al., 2012; 22485171, Kim et al., 2014; 23649938). Loss of functional ATM results in a defective DNA damage response and homologous recombination_mediated DNA repair and may predict sensitivity to PARP inhibitors (Michels et al., 2014; 24037533). Clinical data in prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), gastric cancer (Bang et al., 2015; 26282658), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), papillary renal cell carcinoma (Olson et al., 2016; 27079472), and cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096) indicate that loss or inactivation of ATM may confer sensitivity to PARP inhibitors (Weston et al., 2010; 20739657, Williamson et al., 2010; 20124459, Gilardini et al., 2013; 24252502, Bryant and Helleday, 2006; 16556909, Ihnen et al., 2013; 23729402, Williamson et al., 2012; 22416035, Kubota et al., 2014; 24841718, Huehls et al., 2012; 22833573). In Phase 1 trials of ATR inhibitors, a heavily pretreated patient with colorectal cancer who achieved a CR to berzosertib (O Carrigan et al., 2016; ASCO Abstract 2504) and 4 out of 4 patients with diverse solid tumors who achieved PRs to BAY1895344 (Yap et al., 2020; 32988960) harbored ATM inactivation or protein loss; studies showing reduced cell viability and increased DNA damage in preclinical models of solid tumors (Menezes et al., 2015; 25232030, Vendetti et al., 2015; 26517239, Min et al., 2017; 28138034) and hematologic malignancies (Menezes et al., 2015; 25232030, Kwok et al., 2016; 26563132) also support the increased sensitivity of ATM_deficient cells to ATR inhibitors. Preclinical experiments also indicate that loss of ATM causes dependency on DNA_PKcs in cancer cells; DNA_PKcs inhibitors promoted apoptosis in ATM_deficient cells and were active in a lymphoma mouse model lacking ATM activity (Riabinska et al., 2013; 23761041). ATM mutation carriers have increased cancer risk, with female carriers displaying a 38% lifetime risk of breast cancer (van Os et al., 2016; 26662178). Biallelic mutations in ATM underlie the rare autosomal_recessive inherited disorder ataxia_telangiectasia (A_T), also referred to as genome instability or DNA damage response syndrome (Rothblum_Oviatt et al., 2016; 27884168). This disease is characterized by genomic instability, sensitivity to DNA_damaging agents, and increased risk of developing cancer (Shiloh and Ziv, 2013; 23847781, Rothblum_Oviatt et al., 2016; 27884168). The prevalence of A_T is estimated at 1:40,000 to 1:100,000 worldwide (Rothblum_Oviatt et al., 2016; 27884168). In the appropriate clinical context, germline testing of ATM is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Rucaparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration_resistant prostate cancer (mCRPC) or epithelial ovarian, Fallopian tube, or primary peritoneal cancer and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). </p> <p><b>Supporting Data:</b> Rucaparib has primarily been evaluated in the context of ovarian carcinoma, breast carcinoma, pancreatic carcinoma, and melanoma. In a Phase 2 study of rucaparib for recurrent, platinum_sensitive ovarian, peritoneal, or fallopian tube carcinoma, median PFS was significantly longer in patients with BRCA1/2 mutations (12.8 months) or high loss of heterozygosity (LOH; 5.7 months) compared to patients with low LOH (5.2 months). Objective responses were observed for 80% (32/40) of patients with BRCA1/2 mutations, for 29% (24/82) with high LOH, and for 10% (7/10) with low LOH (Swisher et al., 2016; 27908594). In heavily pretreated patients with a germline BRCA1/2 mutation who had received 2_4 prior chemotherapy treatments and had a progression free interval of greater than 6 months, 65% (17/26) of patients achieved an objective response with rucaparib treatment (Shapira_Frommer et al., 2015; ASCO Abstract 5513). In a Phase 2 study evaluating rucaparib for patients with advanced breast or ovarian cancer and germline BRCA1/2 mutations, disease control was observed in 92% (12/13) of patients with ovarian cancer treated with oral rucaparib dosed continuously, but no objective responses were reported in breast cancer patients (n=23). However, 39% (9/23) of evaluable patients with breast cancer achieved SD lasting 12 weeks or more (Drew et al., 2016; 27002934). In a Phase 1 study of rucaparib treatment in patients with solid tumors, 3/4 patients with ovarian cancer and 1/1 patient with breast cancer given the recommended Phase 2 dose reported objective responses; all responders harbored BRCA1/2 mutations (Kristeleit et al., 2014; ASCO Abstract 2573). A Phase 2 study of rucaparib treatment for patients with relapsed pancreatic cancer reported 1/19 CR, 2/19 PR (one unconfirmed) and 4/19 SD. Of the 19 patients treated in the study, 15 (79%) had a BRCA2 mutation (Domcheck et al., 2016; ASCO Abstract 4110). In a Phase 2 study of intravenous rucaparib in combination with temozolomide for patients with metastatic melanoma, 8/46 patients achieved a PR and 8/46 had SD (Plummer et al., 2013; 23423489); a Phase 1 study reported 1 CR, 1 PR, and 4 SD lasting six months or longer in patients with metastatic melanoma (Plummer et al., 2008; 19047122). A Phase 1 study of intravenous and oral rucaparib in combination with chemotherapy for the treatment of advanced solid tumors reported a disease control rate of 68.8% (53/77), including 1 CR and 9 PRs (Wilson et al., 2017; 28222073). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Niraparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)_positive status. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). </p> <p><b>Supporting Data:</b> Niraparib has been primarily evaluated in the context of ovarian cancer. In a Phase 3 study of patients with platinum_sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS, as compared to placebo, in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months) as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination_deficient tumors (12.9 vs. 3.8 months)(Mirza et al., 2016; 27717299). In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration_resistant prostate cancer and 100% (2/2) of patients with non_small cell lung cancer achieved SD (Sandhu et al., 2013; 23810788). A Phase 1 study of the combination of niraparib and bevacizumab in patients with platinum_sensitive, high_grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)(Mirza et al., 2016; ASCO Abstract 5555). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Olaparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA_mutated pancreatic adenocarcinoma or HER2_negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). </p> <p><b>Supporting Data:</b> Olaparib has been studied primarily for the treatment of ovarian cancer, with response rates often significantly higher for patients with BRCA mutations than for those without (Fong et al., 2009; 19553641, Gelmon et al., 2011; 21862407); higher response rates have also been observed for patients with platinum_sensitive versus platinum_resistant cancer (Domchek et al., 2016; 26723501, Matulonis et al., 2016; 26961146, Gelmon et al., 2011; 21862407, Fong et al., 2010; 20406929). As maintenance therapy for patients with newly diagnosed or platinum_sensitive relapsed ovarian cancer, olaparib has demonstrated significantly improved median PFS and median OS compared with placebo in the Phase 3 SOLO_1 study (Moore et al., 2018; 30345884) and in multiple later_phase studies (Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Ledermann et al., 2012; 22452356, Ledermann et al., 2014; 24882434). Phase 3 studies of olaparib for patients with BRCA_mutated metastatic breast (Robson et al., 2017; 28578601) or pancreatic cancer (Golan et al., 2019; 31157963) or for patients with metastatic castration_resistant prostate cancer and BRCA or ATM alterations (de Bono et al., 2020; 32343890) have also reported significantly longer median PFS compared with chemotherapy, placebo, or hormone therapy. Additionally, olaparib has demonstrated clinical activity for patients with other solid tumors harboring BRCA mutations, including leiomyosarcoma (Seligson et al., 2019; 30541756), cholangiocarcinoma (Lin et al., 2019; 31068370), and bladder cancer (Necchi et al., 2018; 29680362) in smaller studies. Olaparib in combination with the AKT inhibitor capivasertib has demonstrated clinical benefit for patients with solid tumors; a Phase 1 trial reported a 45% (25/56) DCR, including 14 PRs and 11 SDs, and 14 of those experiencing clinical benefit had germline BRCA1/2 mutated_solid tumors (Yap et al., 2020; 3253274). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Talazoparib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The PARP inhibitor talazoparib is FDA approved to treat HER2_negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). </p> <p><b>Supporting Data:</b> Talazoparib has been studied primarily in the context of BRCA_mutated, HER2_negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study (Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753). In a Phase 2 study of talazoparib for BRCA1/2_wildtype patients with homologous recombination pathway alterations, the best outcome in non_breast tumors was SD \u2265 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration (Gruber et al., 2019; ASCO Abstract 3006). Clinical activity of single_agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA_mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2_mutated pancreatic and bladder cancers; ATM_mutated cholangiocarcinoma; and small cell lung cancer (deBono et al., 2017; 28242752, Lu et al., 2018; 30099369)(Piha_Paul et al., 2017; EORTC_NCI_AACR Abstract A096, Meehan et al., 2017; AACR Abstract 4687). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03498521", "Include": "true"}, {"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT02630199", "Include": "true"}, {"nctId": "NCT04635631", "Include": "true"}, {"nctId": "NCT03188965", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT02693535", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ASXL1", "Include": "true", "Alterations": {"Alteration": {"Name": "G646fs*12", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "G646fs*12"}}, "Interpretation": "ASXL1 regulates epigenetic marks and transcription through interaction with polycomb complex proteins and various transcription activators and repressors (Scheuermann et al., 2010; 20436459, Cho et al., 2006; 16606617, Park et al., 2011; 21047783). Alterations such as seen here may disrupt ASXL1 function or expression (Inoue et al., 2013; 24216483, Abdel_Wahab et al., 2012; 22897849, Katoh et al., 2013; 23736028). ASXL1 alterations occur infrequently across various solid tumor types (cBio_Zehir et al., 2017; 28481359) and are not known to act as drivers in any specific solid cancer type (Bailey et al., 2018; 29625053). Published data investigating the prognostic implications of ASXL1 alterations in solid tumors are limited (PubMed, May 2021). In the context of clonal hematopoiesis, ASXL1 mutations are significantly enriched in current or former smokers (Bolton et al., 2020; 33106634). There are no targeted therapies available to address genomic alterations in ASXL1. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of TMB have mainly been investigated in the context of tissue TMB. In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high_TMB samples each), but not BRAF (10.3%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong link (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117) and with microsatellite instability (MSI) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117), which in turn has been reported to correlate with better prognosis (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network., 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559) and bladder cancer (Cazier et al., 2016; 24777035), it is also linked with improved prognosis in patients with these tumor types (Rosenberg et al., 2016; ASCO Abstract 104, Cancer Genome Atlas Research Network., 2013; 23636398). On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511) and anti_PD_1 (Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074) therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In HNSCC, a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear. While approximately 80% of MSI_H tumors arise due to somatic inactivation of an MMR pathway protein, about 20% arise due to germline mutations in one of the MMR genes (Kocarnik et al., 2015; 26337942), which are associated with a condition known as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) (Lynch et al., 2009; 19659756). Lynch syndrome leads to an increased risk of colorectal, endometrial, gastric, and other cancers (Lynch et al., 2009; 19659756, Pande et al., 2012; 22714864, Kastrinos and Syngal, 2007; 17920897) and has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Therefore, in the appropriate clinical context, germline testing of MLH1, MSH2, MSH6, and PMS2 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TERT", "Include": "true", "Alterations": {"Alteration": {"Name": "promoter _124C>T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "promoter _124C>T"}}, "Interpretation": "Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80_90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at _124 bp and _146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions \u2013124/\u2013125 bp and \u2013138/\u2013139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been observed in melanoma, glioma, and thyroid and bladder cancers (Vinagre et al., 2013; 23887589, Huang et al., 2014; 23348506, Pinyol et al., 2014; 24859456, Rachakonda et al., 2013; 24101484, Liu et al., 2013; 23766237, Landa et al., 2013; 23833040, Nonoguchi et al., 2013; 23955565, Liu et al., 2013; 23603989, Killela et al., 2013; 23530248) and associate with increased TERT expression (Heidenreich et al., 2014; 24569790, Huang et al., 2013; 23348506, Horn et al., 2013; 23348503). In thyroid tumors, these promoter mutations were shown to be associated with tumor aggressiveness and increased mortality, and often coincided with BRAF or RAS alterations (Xing et al., 2014; 25024077, Vinagre et al., 2013; 23887589, Landa et al., 2013; 23833040, Liu et al., 2013; 23766237). In melanoma, TERT promoter mutations or protein overexpression has been associated with poor clinicopathological features, but not with impact on survival (Populo et al., 2014; 24691053, Eqberts et al., 2014; 24463461, Heidenreich et al., 2014; 24569790, Zygouris et al., 2007; 18067210). In addition, germline polymorphisms in TERT have been associated with risk of melanoma development (Law et al., 2012; 21993562, Yin et al., 2012; 23226346, Nan et al., 2011; 21116649). TERT promoter mutations were significantly associated with poor survival in patients with urothelial cell carcinoma, but only in the absence of a common polymorphism (rs2853669) that was reported in 47% of patients (Rachakonda et al., 2013; 24101484). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches are under development, including immunotherapies utilizing TERT as a tumor_associated antigen, antisense oligonucleotide_ or peptide_based therapies, and TERT promoter_directed cytotoxic molecules.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "20", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "20"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with high tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results (Li et al., 2021; AACR Abstract 2231). However, if tumor fraction is not detected as high, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "ARID1A", "Alteration": "splice site 2732+1_2732+18del18", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "splice site 2732+1_2732+18del18", "Title": "Study of AZD6738, DNA Damage Repair/Novel Anti_cancer Agent, in Combination With Paclitaxel, in Refractory Cancer", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT02630199", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "splice site 2732+1_2732+18del18", "Title": "M6620 Plus Standard Treatment in Oesophageal and Other Cancer", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Glasgow (United Kingdom), Manchester (United Kingdom), Oxford (United Kingdom), Cardiff (United Kingdom)", "NCTID": "NCT03641547", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "splice site 2732+1_2732+18del18", "Title": "AZD6738 & Gemcitabine as Combination Therapy", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Cambridge (United Kingdom)", "NCTID": "NCT03669601", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "splice site 2732+1_2732+18del18", "Title": "ATR Kinase Inhibitor VX_970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "California, Missouri, Pennsylvania, Massachusetts, Connecticut, Tennessee, Florida", "NCTID": "NCT02595931", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum_Based Chemotherapy in Patients With Cancer of Unknown Primary Site", "StudyPhase": "PHASE 2", "Target": "ALK, RET, SMO, AKTs, PARP, PD_L1, EGFR, VEGFA, MEK, BRAF, ERBB2, ERBB3, ROS1, TRKA, TRKB, TRKC", "Locations": "Fukuoka (Japan), Ehime (Japan), Seoul (Korea, Republic of), Aichi (Japan), Tokyo (Japan), Chiba (Japan), Bangkok (Thailand), Blacktown (Australia), St Leonards (Australia), Helsinki (Finland)", "NCTID": "NCT03498521", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)", "NCTID": "NCT03742895", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "Study of AZD6738, DNA Damage Repair/Novel Anti_cancer Agent, in Combination With Paclitaxel, in Refractory Cancer", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT02630199", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Beijing (China), Changchun (China)", "NCTID": "NCT04635631", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "First_in_human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Sunto (Japan), Chuo_ku (Japan), Kashiwa (Japan), Singapore (Singapore), St. Gallen (Switzerland), Bellinzona (Switzerland), Newcastle Upon Tyne (United Kingdom), Gen\u00e8ve (Switzerland), Sutton (United Kingdom), Edmonton (Canada)", "NCTID": "NCT03188965", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}, {"Gene": "ATM", "Alteration": "splice site 6007_1G>T", "Title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, CDK4, CDK6, CSF1R, FLT3, KIT, RET, mTOR, EGFR, ERBB2, ERBB3, MEK, BRAF, SMO, DDR2, PARP, PD_1, CTLA_4, ERBB4", "Locations": "Hawaii, Washington, Oregon, California", "NCTID": "NCT02693535", "Note": "Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "23847781", "FullCitation": "Shiloh Y, et al. Nat. Rev. Mol. Cell Biol. (2013) pmid: 23847781", "Include": "true"}, {"number": "1", "ReferenceId": "23851492", "FullCitation": "Cremona CA, et al. Oncogene (2014) pmid: 23851492", "Include": "true"}, {"number": "2", "ReferenceId": "16603769", "FullCitation": "Jiang X, et al. J. Biol. Chem. (2006) pmid: 16603769", "Include": "true"}, {"number": "3", "ReferenceId": "15713674", "FullCitation": "Fernandes N, et al. J. Biol. Chem. (2005) pmid: 15713674", "Include": "true"}, {"number": "4", "ReferenceId": "11805335", "FullCitation": "Scott SP, et al. Proc. Natl. Acad. Sci. U.S.A. (2002) pmid: 11805335", "Include": "true"}, {"number": "5", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "6", "ReferenceId": "23437304", "FullCitation": "Wu CW, et al. PLoS ONE (2013) pmid: 23437304", "Include": "true"}, {"number": "7", "ReferenceId": "17928013", "FullCitation": "Kang B, et al. Mutat. Res. (2008) pmid: 17928013", "Include": "true"}, {"number": "8", "ReferenceId": "23328638", "FullCitation": "Kim HS, et al. Pathobiology (2013) pmid: 23328638", "Include": "true"}, {"number": "9", "ReferenceId": "23569343", "FullCitation": "Zhang ZZ, et al. World J. Gastroenterol. (2013) pmid: 23569343", "Include": "true"}, {"number": "10", "ReferenceId": "22707287", "FullCitation": "Shin JU, et al. Tumour Biol. (2012) pmid: 22707287", "Include": "true"}, {"number": "11", "ReferenceId": "16533773", "FullCitation": "Grabsch H, et al. Clin. Cancer Res. (2006) pmid: 16533773", "Include": "true"}, {"number": "12", "ReferenceId": "22485171", "FullCitation": "Lee J, et al. PLoS ONE (2012) pmid: 22485171", "Include": "true"}, {"number": "13", "ReferenceId": "23649938", "FullCitation": "Kim JW, et al. Int. J. Cancer (2014) pmid: 23649938", "Include": "true"}, {"number": "14", "ReferenceId": "24037533", "FullCitation": "Michels J, et al. Oncogene (2014) pmid: 24037533", "Include": "true"}, {"number": "15", "ReferenceId": "26510020", "FullCitation": "Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020", "Include": "true"}, {"number": "16", "ReferenceId": "31806540", "FullCitation": "Mateo J, et al. Lancet Oncol. (2019) pmid: 31806540", "Include": "true"}, {"number": "17", "ReferenceId": "32086346", "FullCitation": "Abida W, et al. Clin. Cancer Res. (2020) pmid: 32086346", "Include": "true"}, {"number": "18", "ReferenceId": "26282658", "FullCitation": "Bang YJ, et al. J. Clin. Oncol. (2015) pmid: 26282658", "Include": "true"}, {"number": "19", "ReferenceId": "27079472", "FullCitation": "Olson D, et al. Clin Genitourin Cancer (2016) pmid: 27079472", "Include": "true"}, {"number": "20", "ReferenceId": "20739657", "FullCitation": "Weston VJ, et al. Blood (2010) pmid: 20739657", "Include": "true"}, {"number": "21", "ReferenceId": "20124459", "FullCitation": "Williamson CT, et al. Mol. Cancer Ther. (2010) pmid: 20124459", "Include": "true"}, {"number": "22", "ReferenceId": "24252502", "FullCitation": "Gilardini Montani MS, et al. J. Exp. Clin. Cancer Res. (2013) pmid: 24252502", "Include": "true"}, {"number": "23", "ReferenceId": "16556909", "FullCitation": "Bryant HE, et al. Nucleic Acids Res. (2006) pmid: 16556909", "Include": "true"}, {"number": "24", "ReferenceId": "23729402", "FullCitation": "Ihnen M, et al. Mol. Cancer Ther. (2013) pmid: 23729402", "Include": "true"}, {"number": "25", "ReferenceId": "22416035", "FullCitation": "Williamson CT, et al. EMBO Mol Med (2012) pmid: 22416035", "Include": "true"}, {"number": "26", "ReferenceId": "24841718", "FullCitation": "Kubota E, et al. Cell Cycle (2014) pmid: 24841718", "Include": "true"}, {"number": "27", "ReferenceId": "22833573", "FullCitation": "Huehls AM, et al. Mol. Pharmacol. (2012) pmid: 22833573", "Include": "true"}, {"number": "28", "ReferenceId": "32988960", "FullCitation": "Yap TA, et al. Cancer Discov (2021) pmid: 32988960", "Include": "true"}, {"number": "29", "ReferenceId": "25232030", "FullCitation": "Menezes DL, et al. Mol. Cancer Res. (2015) pmid: 25232030", "Include": "true"}, {"number": "30", "ReferenceId": "26517239", "FullCitation": "Vendetti FP, et al. Oncotarget (2015) pmid: 26517239", "Include": "true"}, {"number": "31", "ReferenceId": "28138034", "FullCitation": "Min A, et al. Mol. Cancer Ther. (2017) pmid: 28138034", "Include": "true"}, {"number": "32", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "33", "ReferenceId": "23761041", "FullCitation": "Riabinska A, et al. Sci Transl Med (2013) pmid: 23761041", "Include": "true"}, {"number": "34", "ReferenceId": "26662178", "FullCitation": "van Os NJ, et al. Clin Genet (2016) pmid: 26662178", "Include": "true"}, {"number": "35", "ReferenceId": "27884168", "FullCitation": "Rothblum_Oviatt C, et al. Orphanet J Rare Dis (2016) pmid: 27884168", "Include": "true"}, {"number": "36", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "37", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "38", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "39", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "40", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "41", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "42", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "43", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "44", "ReferenceId": "21900401", "FullCitation": "Guan B, et al. Cancer Res. (2011) pmid: 21900401", "Include": "true"}, {"number": "45", "ReferenceId": "22009941", "FullCitation": "Jones S, et al. Hum. Mutat. (2012) pmid: 22009941", "Include": "true"}, {"number": "46", "ReferenceId": "20942669", "FullCitation": "Wiegand KC, et al. N. Engl. J. Med. (2010) pmid: 20942669", "Include": "true"}, {"number": "47", "ReferenceId": "20826764", "FullCitation": "Jones S, et al. Science (2010) pmid: 20826764", "Include": "true"}, {"number": "48", "ReferenceId": "24293408", "FullCitation": "Yan HB, et al. Carcinogenesis (2014) pmid: 24293408", "Include": "true"}, {"number": "49", "ReferenceId": "22808142", "FullCitation": "Wang DD, et al. PLoS ONE (2012) pmid: 22808142", "Include": "true"}, {"number": "50", "ReferenceId": "22922871", "FullCitation": "Huang J, et al. Nat. Genet. (2012) pmid: 22922871", "Include": "true"}, {"number": "51", "ReferenceId": "24185513", "FullCitation": "Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513", "Include": "true"}, {"number": "52", "ReferenceId": "21892209", "FullCitation": "Mamo A, et al. Oncogene (2012) pmid: 21892209", "Include": "true"}, {"number": "53", "ReferenceId": "22484628", "FullCitation": "Zang ZJ, et al. Nat. Genet. (2012) pmid: 22484628", "Include": "true"}, {"number": "54", "ReferenceId": "22037554", "FullCitation": "Wang K, et al. Nat. Genet. (2011) pmid: 22037554", "Include": "true"}, {"number": "55", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "56", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "57", "ReferenceId": "24618703", "FullCitation": "Wu RC, et al. Cancer Biol. Ther. (2014) pmid: 24618703", "Include": "true"}, {"number": "58", "ReferenceId": "23525077", "FullCitation": "Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077", "Include": "true"}, {"number": "59", "ReferenceId": "23318448", "FullCitation": "Streppel MM, et al. Oncogene (2014) pmid: 23318448", "Include": "true"}, {"number": "60", "ReferenceId": "24293293", "FullCitation": "Jiao Y, et al. J. Pathol. (2014) pmid: 24293293", "Include": "true"}, {"number": "61", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "62", "ReferenceId": "25195947", "FullCitation": "Huang HN, et al. Histopathology (2015) pmid: 25195947", "Include": "true"}, {"number": "63", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "64", "ReferenceId": "23702729", "FullCitation": "Bosse T, et al. Mod. Pathol. (2013) pmid: 23702729", "Include": "true"}, {"number": "65", "ReferenceId": "23887303", "FullCitation": "Allo G, et al. Mod. Pathol. (2014) pmid: 23887303", "Include": "true"}, {"number": "66", "ReferenceId": "32111729", "FullCitation": "Okamura R, et al. J Immunother Cancer (2020) pmid: 32111729", "Include": "true"}, {"number": "67", "ReferenceId": "24925223", "FullCitation": "Chou A, et al. Hum. Pathol. (2014) pmid: 24925223", "Include": "true"}, {"number": "68", "ReferenceId": "25311944", "FullCitation": "Ye J, et al. Hum. Pathol. (2014) pmid: 25311944", "Include": "true"}, {"number": "69", "ReferenceId": "25561809", "FullCitation": "Wei XL, et al. World J. Gastroenterol. (2014) pmid: 25561809", "Include": "true"}, {"number": "70", "ReferenceId": "25583476", "FullCitation": "Chen K, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25583476", "Include": "true"}, {"number": "71", "ReferenceId": "22915242", "FullCitation": "Abe H, et al. Virchows Arch. (2012) pmid: 22915242", "Include": "true"}, {"number": "72", "ReferenceId": "24767857", "FullCitation": "Wiegand KC, et al. Hum. Pathol. (2014) pmid: 24767857", "Include": "true"}, {"number": "73", "ReferenceId": "22274316", "FullCitation": "Katagiri A, et al. Int. J. Gynecol. Cancer (2012) pmid: 22274316", "Include": "true"}, {"number": "74", "ReferenceId": "23427874", "FullCitation": "Cho H, et al. Hum. Pathol. (2013) pmid: 23427874", "Include": "true"}, {"number": "75", "ReferenceId": "21822268", "FullCitation": "Gui Y, et al. Nat. Genet. (2011) pmid: 21822268", "Include": "true"}, {"number": "76", "ReferenceId": "23650517", "FullCitation": "Balb\u00e1s_Mart\u00ednez C, et al. PLoS ONE (2013) pmid: 23650517", "Include": "true"}, {"number": "77", "ReferenceId": "25175170", "FullCitation": "Faraj SF, et al. Hum. Pathol. (2014) pmid: 25175170", "Include": "true"}, {"number": "78", "ReferenceId": "22939958", "FullCitation": "Rahman M, et al. Hum. Pathol. (2013) pmid: 22939958", "Include": "true"}, {"number": "79", "ReferenceId": "21614196", "FullCitation": "Maeda D, et al. Int J Mol Sci (2010) pmid: 21614196", "Include": "true"}, {"number": "80", "ReferenceId": "22193641", "FullCitation": "Lowery WJ, et al. Int. J. Gynecol. Cancer (2012) pmid: 22193641", "Include": "true"}, {"number": "81", "ReferenceId": "23524907", "FullCitation": "Fadare O, et al. Mod. Pathol. (2013) pmid: 23524907", "Include": "true"}, {"number": "82", "ReferenceId": "24076775", "FullCitation": "Mao TL, et al. Am. J. Surg. Pathol. (2013) pmid: 24076775", "Include": "true"}, {"number": "83", "ReferenceId": "22101352", "FullCitation": "Katagiri A, et al. Mod. Pathol. (2012) pmid: 22101352", "Include": "true"}, {"number": "84", "ReferenceId": "21889920", "FullCitation": "Zhang X, et al. Cancer Epidemiol (2012) pmid: 21889920", "Include": "true"}, {"number": "85", "ReferenceId": "24430365", "FullCitation": "Zhao J, et al. Tumour Biol. (2014) pmid: 24430365", "Include": "true"}, {"number": "86", "ReferenceId": "23416164", "FullCitation": "Lichner Z, et al. Am. J. Pathol. (2013) pmid: 23416164", "Include": "true"}, {"number": "87", "ReferenceId": "33387086", "FullCitation": "Feng F, et al. Int J Clin Oncol (2021) pmid: 33387086", "Include": "true"}, {"number": "88", "ReferenceId": "32020551", "FullCitation": "Conci S, et al. Updates Surg (2020) pmid: 32020551", "Include": "true"}, {"number": "89", "ReferenceId": "29740198", "FullCitation": "Simbolo M, et al. Sci Rep (2018) pmid: 29740198", "Include": "true"}, {"number": "90", "ReferenceId": "26717940", "FullCitation": "Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940", "Include": "true"}, {"number": "91", "ReferenceId": "29252124", "FullCitation": "Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124", "Include": "true"}, {"number": "92", "ReferenceId": "27958275", "FullCitation": "Williamson CT, et al. Nat Commun (2016) pmid: 27958275", "Include": "true"}, {"number": "93", "ReferenceId": "25686104", "FullCitation": "Bitler BG, et al. Nat. Med. (2015) pmid: 25686104", "Include": "true"}, {"number": "94", "ReferenceId": "26552009", "FullCitation": "Kim KH, et al. Nat. Med. (2015) pmid: 26552009", "Include": "true"}, {"number": "95", "ReferenceId": "24559118", "FullCitation": "Wiegand KC, et al. BMC Cancer (2014) pmid: 24559118", "Include": "true"}, {"number": "96", "ReferenceId": "24336158", "FullCitation": "Huang HN, et al. Mod. Pathol. (2014) pmid: 24336158", "Include": "true"}, {"number": "97", "ReferenceId": "24979463", "FullCitation": "Samartzis EP, et al. Oncotarget (2014) pmid: 24979463", "Include": "true"}, {"number": "98", "ReferenceId": "24459582", "FullCitation": "Yokoyama Y, et al. J Gynecol Oncol (2014) pmid: 24459582", "Include": "true"}, {"number": "99", "ReferenceId": "24833095", "FullCitation": "Xie C, et al. Tumour Biol. (2014) pmid: 24833095", "Include": "true"}, {"number": "100", "ReferenceId": "20436459", "FullCitation": "Scheuermann JC, et al. Nature (2010) pmid: 20436459", "Include": "true"}, {"number": "101", "ReferenceId": "16606617", "FullCitation": "Cho YS, et al. J. Biol. Chem. (2006) pmid: 16606617", "Include": "true"}, {"number": "102", "ReferenceId": "21047783", "FullCitation": "Park UH, et al. J. Biol. Chem. (2011) pmid: 21047783", "Include": "true"}, {"number": "103", "ReferenceId": "24216483", "FullCitation": "Inoue D, et al. J. Clin. Invest. (2013) pmid: 24216483", "Include": "true"}, {"number": "104", "ReferenceId": "22897849", "FullCitation": "Abdel_Wahab O, et al. Cancer Cell (2012) pmid: 22897849", "Include": "true"}, {"number": "105", "ReferenceId": "23736028", "FullCitation": "Br. J. Cancer (2013) pmid: 23736028", "Include": "true"}, {"number": "106", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "107", "ReferenceId": "29625053", "FullCitation": "Bailey MH, et al. Cell (2018) pmid: 29625053", "Include": "true"}, {"number": "108", "ReferenceId": "33106634", "FullCitation": "Bolton KL, et al. Nat Genet (2020) pmid: 33106634", "Include": "true"}, {"number": "109", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "110", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "111", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "112", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "113", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "114", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "115", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "116", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "117", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "118", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "119", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "120", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "121", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "122", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "123", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "124", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "125", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "126", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "127", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "128", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "129", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "130", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "131", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "132", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "133", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "134", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "135", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "136", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "137", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "138", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "139", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "140", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "141", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "142", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "143", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "144", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "145", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "146", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "147", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "148", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "149", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "150", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "151", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "152", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "153", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "154", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "155", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "156", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "157", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "158", "ReferenceId": "19659756", "FullCitation": "Lynch HT, et al. Clin. Genet. (2009) pmid: 19659756", "Include": "true"}, {"number": "159", "ReferenceId": "22714864", "FullCitation": "Pande M, et al. Fam. Cancer (2012) pmid: 22714864", "Include": "true"}, {"number": "160", "ReferenceId": "17920897", "FullCitation": "Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897", "Include": "true"}, {"number": "161", "ReferenceId": "19466295", "FullCitation": "Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295", "Include": "true"}, {"number": "162", "ReferenceId": "24978665", "FullCitation": "Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665", "Include": "true"}, {"number": "163", "ReferenceId": "16136383", "FullCitation": "Fam. Cancer (2005) pmid: 16136383", "Include": "true"}, {"number": "164", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "165", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "166", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "167", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "168", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "169", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "170", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "171", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "172", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "173", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "174", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "175", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "176", "ReferenceId": "27009843", "FullCitation": "Xiao D, et al. Oncotarget (2016) pmid: 27009843", "Include": "true"}, {"number": "177", "ReferenceId": "26200269", "FullCitation": "Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269", "Include": "true"}, {"number": "178", "ReferenceId": "22980976", "FullCitation": "Govindan R, et al. Cell (2012) pmid: 22980976", "Include": "true"}, {"number": "179", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "180", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "181", "ReferenceId": "24323028", "FullCitation": "Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028", "Include": "true"}, {"number": "182", "ReferenceId": "27022117", "FullCitation": "Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117", "Include": "true"}, {"number": "183", "ReferenceId": "11535541", "FullCitation": "Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541", "Include": "true"}, {"number": "184", "ReferenceId": "12445368", "FullCitation": "Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368", "Include": "true"}, {"number": "185", "ReferenceId": "12820457", "FullCitation": "Brueckl WM, et al. Anticancer Res. () pmid: 12820457", "Include": "true"}, {"number": "186", "ReferenceId": "11438476", "FullCitation": "Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476", "Include": "true"}, {"number": "187", "ReferenceId": "10631274", "FullCitation": "Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274", "Include": "true"}, {"number": "188", "ReferenceId": "16952542", "FullCitation": "Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542", "Include": "true"}, {"number": "189", "ReferenceId": "22722556", "FullCitation": "Laghi L, et al. Dig Dis (2012) pmid: 22722556", "Include": "true"}, {"number": "190", "ReferenceId": "27159395", "FullCitation": "Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395", "Include": "true"}, {"number": "191", "ReferenceId": "23528559", "FullCitation": "Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559", "Include": "true"}, {"number": "192", "ReferenceId": "24777035", "FullCitation": "Cazier JB, et al. Nat Commun (2014) pmid: 24777035", "Include": "true"}, {"number": "193", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "194", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "195", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "196", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "197", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "198", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "199", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "200", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "201", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "202", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "203", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "204", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "205", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "206", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "207", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "208", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "209", "ReferenceId": "22015685", "FullCitation": "Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685", "Include": "true"}, {"number": "210", "ReferenceId": "9282118", "FullCitation": "Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118", "Include": "true"}, {"number": "211", "ReferenceId": "7605428", "FullCitation": "Kim NW, et al. Science (1994) pmid: 7605428", "Include": "true"}, {"number": "212", "ReferenceId": "10647931", "FullCitation": "Hanahan D, et al. Cell (2000) pmid: 10647931", "Include": "true"}, {"number": "213", "ReferenceId": "23348503", "FullCitation": "Horn S, et al. Science (2013) pmid: 23348503", "Include": "true"}, {"number": "214", "ReferenceId": "23348506", "FullCitation": "Huang FW, et al. Science (2013) pmid: 23348506", "Include": "true"}, {"number": "215", "ReferenceId": "23887589", "FullCitation": "Vinagre J, et al. Nat Commun (2013) pmid: 23887589", "Include": "true"}, {"number": "216", "ReferenceId": "24859456", "FullCitation": "Pinyol R, et al. J. Hepatol. (2014) pmid: 24859456", "Include": "true"}, {"number": "217", "ReferenceId": "24101484", "FullCitation": "Rachakonda PS, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 24101484", "Include": "true"}, {"number": "218", "ReferenceId": "23766237", "FullCitation": "Liu X, et al. Endocr. Relat. Cancer (2013) pmid: 23766237", "Include": "true"}, {"number": "219", "ReferenceId": "23833040", "FullCitation": "Landa I, et al. J. Clin. Endocrinol. Metab. (2013) pmid: 23833040", "Include": "true"}, {"number": "220", "ReferenceId": "23955565", "FullCitation": "Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565", "Include": "true"}, {"number": "221", "ReferenceId": "23603989", "FullCitation": "Liu X, et al. Cell Cycle (2013) pmid: 23603989", "Include": "true"}, {"number": "222", "ReferenceId": "23530248", "FullCitation": "Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248", "Include": "true"}, {"number": "223", "ReferenceId": "24569790", "FullCitation": "Heidenreich B, et al. Nat Commun (2014) pmid: 24569790", "Include": "true"}, {"number": "224", "ReferenceId": "25024077", "FullCitation": "Xing M, et al. J. Clin. Oncol. (2014) pmid: 25024077", "Include": "true"}, {"number": "225", "ReferenceId": "24691053", "FullCitation": "P\u00f3pulo H, et al. J. Invest. Dermatol. (2014) pmid: 24691053", "Include": "true"}, {"number": "226", "ReferenceId": "24463461", "FullCitation": "Egberts F, et al. Melanoma Res. (2014) pmid: 24463461", "Include": "true"}, {"number": "227", "ReferenceId": "18067210", "FullCitation": "Zygouris P, et al. J BUON () pmid: 18067210", "Include": "true"}, {"number": "228", "ReferenceId": "21993562", "FullCitation": "Law MH, et al. J. Invest. Dermatol. (2012) pmid: 21993562", "Include": "true"}, {"number": "229", "ReferenceId": "23226346", "FullCitation": "Yin J, et al. PLoS ONE (2012) pmid: 23226346", "Include": "true"}, {"number": "230", "ReferenceId": "21116649", "FullCitation": "Nan H, et al. Hum. Genet. (2011) pmid: 21116649", "Include": "true"}, {"number": "231", "ReferenceId": "19553641", "FullCitation": "Fong PC, et al. N. Engl. J. Med. (2009) pmid: 19553641", "Include": "true"}, {"number": "232", "ReferenceId": "21862407", "FullCitation": "Gelmon KA, et al. Lancet Oncol. (2011) pmid: 21862407", "Include": "true"}, {"number": "233", "ReferenceId": "26723501", "FullCitation": "Domchek SM, et al. Gynecol. Oncol. (2016) pmid: 26723501", "Include": "true"}, {"number": "234", "ReferenceId": "26961146", "FullCitation": "Matulonis UA, et al. Ann. Oncol. (2016) pmid: 26961146", "Include": "true"}, {"number": "235", "ReferenceId": "20406929", "FullCitation": "Fong PC, et al. J. Clin. Oncol. (2010) pmid: 20406929", "Include": "true"}, {"number": "236", "ReferenceId": "30345884", "FullCitation": "Moore K, et al. N. Engl. J. Med. (2018) pmid: 30345884", "Include": "true"}, {"number": "237", "ReferenceId": "28754483", "FullCitation": "Pujade_Lauraine E, et al. Lancet Oncol. (2017) pmid: 28754483", "Include": "true"}, {"number": "238", "ReferenceId": "27617661", "FullCitation": "Ledermann JA, et al. Lancet Oncol. (2016) pmid: 27617661", "Include": "true"}, {"number": "239", "ReferenceId": "22452356", "FullCitation": "Ledermann J, et al. N. Engl. J. Med. (2012) pmid: 22452356", "Include": "true"}, {"number": "240", "ReferenceId": "24882434", "FullCitation": "Ledermann J, et al. Lancet Oncol. (2014) pmid: 24882434", "Include": "true"}, {"number": "241", "ReferenceId": "28578601", "FullCitation": "Robson M, et al. N. Engl. J. Med. (2017) pmid: 28578601", "Include": "true"}, {"number": "242", "ReferenceId": "31157963", "FullCitation": "Golan T, et al. N. Engl. J. Med. (2019) pmid: 31157963", "Include": "true"}, {"number": "243", "ReferenceId": "32343890", "FullCitation": "de Bono J, et al. N. Engl. J. Med. (2020) pmid: 32343890", "Include": "true"}, {"number": "244", "ReferenceId": "30541756", "FullCitation": "Seligson ND, et al. Oncologist (2019) pmid: 30541756", "Include": "true"}, {"number": "245", "ReferenceId": "31068370", "FullCitation": "Lin J, et al. Clin. Cancer Res. (2019) pmid: 31068370", "Include": "true"}, {"number": "246", "ReferenceId": "29680362", "FullCitation": "Necchi A, et al. Eur. J. Cancer (2018) pmid: 29680362", "Include": "true"}, {"number": "247", "ReferenceId": "3253274", "FullCitation": "Vinitski S, et al. Heart Vessels (1988) pmid: 3253274", "Include": "true"}, {"number": "248", "ReferenceId": "27908594", "FullCitation": "Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594", "Include": "true"}, {"number": "249", "ReferenceId": "27002934", "FullCitation": "Drew Y, et al. Br. J. Cancer (2016) pmid: 27002934", "Include": "true"}, {"number": "250", "ReferenceId": "23423489", "FullCitation": "Plummer R, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23423489", "Include": "true"}, {"number": "251", "ReferenceId": "19047122", "FullCitation": "Plummer R, et al. Clin. Cancer Res. (2008) pmid: 19047122", "Include": "true"}, {"number": "252", "ReferenceId": "28222073", "FullCitation": "Wilson RH, et al. Br. J. Cancer (2017) pmid: 28222073", "Include": "true"}, {"number": "253", "ReferenceId": "27717299", "FullCitation": "Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299", "Include": "true"}, {"number": "254", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "255", "ReferenceId": "30110579", "FullCitation": "Litton JK, et al. N. Engl. J. Med. (2018) pmid: 30110579", "Include": "true"}, {"number": "256", "ReferenceId": "30124753", "FullCitation": "Ettl J, et al. Ann. Oncol. (2018) pmid: 30124753", "Include": "true"}, {"number": "257", "ReferenceId": "28242752", "FullCitation": "de Bono J, et al. Cancer Discov (2017) pmid: 28242752", "Include": "true"}, {"number": "258", "ReferenceId": "30099369", "FullCitation": "Lu E, et al. J Natl Compr Canc Netw (2018) pmid: 30099369", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_11_09 22:43:32", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "20%"}]}, "comments": {"comment": {"commentedBy": "Erik Williams, M.D.", "commentedDts": "2021_11_09T21:44:17.000Z", "text": "Genomic findings from circulating cell_free DNA may originate from circulating tumor DNA (ctDNA), germline alterations, or non_tumor somatic alterations, such as clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion. Clinical correlation is needed to determine whether the ATM variant identified in this case is attributable to the patient s adenocarcinoma or is secondary to CH. Testing of a tissue specimen, such as with FoundationOne\u00aeCDx, could help clarify the origin of this variant. See the professional services section for more information."}}, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary adenocarcinoma", "flowcell_analysis": "2000018505", "gender": "male", "pathology_diagnosis": "Adenocarcinoma, liver; cholangio vs met. adeno WAP 04Nov2021", "pipeline_version": "v3.8.2", "purity_assessment": "25.0", "specimen": "ORD_1226643_01*US1183461.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1226643_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1183461.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0021", "cds_effect": "_124C>T", "depth": "3412", "equivocal": "false", "functional_effect": "promoter", "gene": "TERT", "percent_reads": "0.21", "position": "chr5:1295228", "protein_effect": "promoter _124C>T", "status": "known", "strand": "_", "transcript": "NM_198253", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.4745", "cds_effect": "1513G>A", "depth": "2080", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR3", "percent_reads": "47.45", "position": "chr4:1807182", "protein_effect": "V505I", "status": "unknown", "strand": "+", "transcript": "NM_000142", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.5556", "cds_effect": "5490_5501delTGCCGCCACCAC", "depth": "4300", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "MTOR", "percent_reads": "55.56", "position": "chr1:11190697", "protein_effect": "T1834_T1837del", "status": "unknown", "strand": "_", "transcript": "NM_004958", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.4047", "cds_effect": "9406C>T", "depth": "1196", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "40.47", "position": "chr1:16262141", "protein_effect": "R3136C", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.476", "cds_effect": "973G>A", "depth": "1481", "equivocal": "false", "functional_effect": "missense", "gene": "FANCC", "percent_reads": "47.6", "position": "chr9:97887391", "protein_effect": "A325T", "status": "unknown", "strand": "_", "transcript": "NM_000136", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.0098", "cds_effect": "1934_1935insG", "depth": "2047", "equivocal": "false", "functional_effect": "frameshift", "gene": "ASXL1", "percent_reads": "0.98", "position": "chr20:31022449", "protein_effect": "G646fs*12", "status": "known", "strand": "+", "transcript": "NM_015338", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.4702", "cds_effect": "1862C>T", "depth": "1391", "equivocal": "false", "functional_effect": "missense", "gene": "CSF1R", "percent_reads": "47.02", "position": "chr5:149440532", "protein_effect": "T621M", "status": "unknown", "strand": "_", "transcript": "NM_005211", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.0018", "cds_effect": "6007_1G>T", "depth": "4501", "equivocal": "false", "functional_effect": "splice", "gene": "ATM", "percent_reads": "0.18", "position": "chr11:108186549", "protein_effect": "splice site 6007_1G>T", "status": "likely", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.4575", "cds_effect": "1534G>A", "depth": "647", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "45.75", "position": "chr13:110436867", "protein_effect": "A512T", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.0089", "cds_effect": "905G>A", "depth": "783", "equivocal": "false", "functional_effect": "missense", "gene": "ZNF703", "percent_reads": "0.89", "position": "chr8:37555324", "protein_effect": "G302D", "status": "unknown", "strand": "+", "transcript": "NM_025069", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.5047", "cds_effect": "251G>A", "depth": "1070", "equivocal": "false", "functional_effect": "missense", "gene": "GABRA6", "percent_reads": "50.47", "position": "chr5:161115980", "protein_effect": "R84H", "status": "unknown", "strand": "+", "transcript": "NM_000811", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.0111", "cds_effect": "479A>G", "depth": "1352", "equivocal": "false", "functional_effect": "missense", "gene": "C17orf39", "percent_reads": "1.11", "position": "chr17:17948501", "protein_effect": "K160R", "status": "unknown", "strand": "+", "transcript": "NM_024052", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.015", "cds_effect": "2732+1_2732+18del18", "depth": "1000", "equivocal": "false", "functional_effect": "splice", "gene": "ARID1A", "percent_reads": "1.5", "position": "chr1:27089776", "protein_effect": "splice site 2732+1_2732+18del18", "status": "likely", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"allele_fraction": "0.0051", "cds_effect": "1327A>T", "depth": "1186", "equivocal": "false", "functional_effect": "missense", "gene": "RICTOR", "percent_reads": "0.51", "position": "chr5:38964967", "protein_effect": "S443C", "status": "unknown", "strand": "_", "transcript": "NM_152756", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "6", "equivocal": "true", "gene": "STAG2", "number_of_exons": "33 of 33", "position": "chrX:123156434_123234500", "ratio": "0.76", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"copy_number": "6", "equivocal": "true", "gene": "BCORL1", "number_of_exons": "12 of 12", "position": "chrX:129139185_129190111", "ratio": "0.83", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}]}, "rearrangements": {"rearrangement": {"allele_fraction": "0.145", "description": "PIK3C2G(NM_004570) inversion intron 5 _ intron 8", "equivocal": "false", "in_frame": "unknown", "other_gene": "PIK3C2G", "percent_reads": "14.5", "pos1": "chr12:18491325", "pos2": "chr12:18455759", "status": "unknown", "supporting_read_pairs": "39", "targeted_gene": "PIK3C2G", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.79", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_6", "reads_per_million": "24", "status": "unknown", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"organism": "HHV_8", "reads_per_million": "71", "status": "unknown", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"organism": "HPV_18", "reads_per_million": "10", "status": "unknown", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"organism": "HPV_16", "reads_per_million": "133", "status": "likely", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}, {"organism": "HHV_4", "reads_per_million": "1116", "status": "likely", "dna_evidence": {"sample": "SQ_US1183461.01_1"}}]}}}}}